Anhco Nguyen Sells 3,331 Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Anhco Nguyen sold 3,331 shares of the company’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $7.00, for a total transaction of $23,317.00. Following the completion of the sale, the chief executive officer now owns 74,123 shares in the company, valued at approximately $518,861. This trade represents a 4.30 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Atara Biotherapeutics Stock Down 7.0 %

NASDAQ:ATRA opened at $6.80 on Friday. The company’s 50 day moving average price is $9.97 and its 200-day moving average price is $9.73. Atara Biotherapeutics, Inc. has a 52 week low of $5.40 and a 52 week high of $20.81. The stock has a market cap of $39.17 million, a price-to-earnings ratio of -0.26 and a beta of 0.46.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. Canaccord Genuity Group cut their price objective on shares of Atara Biotherapeutics from $21.00 to $17.00 and set a “buy” rating on the stock in a report on Friday, January 17th. Rodman & Renshaw assumed coverage on shares of Atara Biotherapeutics in a report on Friday, December 20th. They issued a “buy” rating and a $25.00 price objective on the stock. RODMAN&RENSHAW cut shares of Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 21st. HC Wainwright restated a “neutral” rating on shares of Atara Biotherapeutics in a report on Tuesday, January 28th. Finally, TD Cowen upgraded shares of Atara Biotherapeutics to a “strong-buy” rating in a report on Friday, November 29th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.75.

Institutional Investors Weigh In On Atara Biotherapeutics

A number of institutional investors have recently made changes to their positions in the company. Bank of America Corp DE grew its holdings in shares of Atara Biotherapeutics by 0.8% during the fourth quarter. Bank of America Corp DE now owns 205,170 shares of the biotechnology company’s stock valued at $2,731,000 after buying an additional 1,543 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in Atara Biotherapeutics during the fourth quarter valued at approximately $48,000. Geode Capital Management LLC lifted its position in Atara Biotherapeutics by 9.5% during the third quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock valued at $380,000 after purchasing an additional 4,043 shares during the period. Citadel Advisors LLC lifted its position in Atara Biotherapeutics by 2.6% during the fourth quarter. Citadel Advisors LLC now owns 267,353 shares of the biotechnology company’s stock valued at $3,558,000 after purchasing an additional 6,873 shares during the period. Finally, FMR LLC lifted its position in Atara Biotherapeutics by 41.7% during the third quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 7,381 shares during the period. Hedge funds and other institutional investors own 70.90% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.